Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Capecitabine + NG-350A |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
| NG-350A | NG350A|NG 350A | CD40 Antibody 16 | NG-350A is an oncolytic adenovirus vector expressing a CD40 monoclonal antibody that activates the immune system for an anti-tumor response (PMID: 31890734). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06459869 | Phase I | Capecitabine + NG-350A | NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (FORTRESS) | Recruiting | USA | GBR | 0 |